The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Tessera Therapeutics secures $150M from Regeneron to develop gene therapy for AATD, a genetic condition affecting the lungs ...
Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.
2h
Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder
Regeneron and Tessera partner on TSRA-196, a one-time gene writing therapy targeting alpha-1 antitrypsin deficiency with FDA ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...
Pharmaceutical Technology on MSN
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback